Pressmeddelanden från Diagonal Bio

Diagonal Bio AB files patent application for Novel Computational Method that significantly improves LAMP primer design

Diagonal Bio AB ("Diagonal Bio" or "the Company"), with its point-of-care analysis system LAMPlify®, has filed a patent application with the...

MFN • 07 Jul 13:00

The Board of Directors of Diagonal Bio carries out a directed issue to underwriters in connection with exercise of warrants of series TO 2

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS,...

MFN • 25 Jun 13:00

Diagonal Bio receives SEK 3.6 million through exercise of warrants of series TO 2

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS,...

MFN • 19 Jun 13:40

Update regarding large shareholder’s exercise of warrants of series TO 2

Yesterday, June 16, 2025, Diagonal Bio AB (“Diagonal Bio” or the “Company”) announced that Stig Aune, one of the Company’s largest sharehold...

MFN • 17 Jun 18:47

Diagonal Bio expands equine panel with addition of strangles

Diagonal Bio AB ("Diagonal Bio" or the "Company"), with the point of care diagnostic system LAMPlify, announces the positive progress of a t...

MFN • 17 Jun 08:30

Large shareholder exercises warrants of series TO 2

Stig Aune, one of Diagonal Bio AB’s ("Diagonal Bio" or the "Company") largest shareholders and the second largest warrant holder has informe...

MFN • 16 Jun 08:30

Last day of trading in Diagonal Bio’s warrants of series TO 2 is 16 June 2025

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS,...

MFN • 13 Jun 08:00

Diagonal Bio shares progress update on LAMPlify® commercial pilots

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") provides a status update on its completed and ongoing LAMPlify® commercial pilots, ...

MFN • 11 Jun 11:30

Svea Bank AB invests SEK 0.5 million in Diagonal Bio AB through the exercise of warrants of series TO 2

Svea Bank AB has informed Diagonal Bio AB ("Diagonal Bio" or the "Company") that Svea Bank AB has exercised all held warrants of series TO 2...

MFN • 09 Jun 14:00

The exercise period for Diagonal Bio’s warrants of series TO 2 starts today

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS,...

MFN • 04 Jun 08:30

Idag, den 20 maj 2025, hölls årsstämma i Diagonal Bio AB. Nedan följer en sammanfattning av de beslut som fattades.

Beslut om fastställande av räkenskaper samt resultatdisposition

MFN • 20 May 14:00

Diagonal Bio secures 100 percent of forthcoming warrant exercise through pre-subscription and underwriting commitments

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") today announces that the Company has agreed on pre-subscription and underwriting co...

MFN • 16 May 12:45

Diagonal Bio publishes interim report for the first quarter of 2025

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") hereby publishes its interim report for the first quarter of 2025.

MFN • 14 May 08:00

Diagonal Bio accelerates its commercialisation efforts with the appointment of Anders Wallseth as Senior Commercial Advisor

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") is pleased to announce the appointment of Anders Wallseth as Senior Commercial Advi...

MFN • 05 May 14:50

Diagonal Bio publishes the Annual Report for 2024

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") today publishes the Company’s annual report for 2024.

MFN • 29 Apr 08:00

Diagonal Bio announces change of news plattform

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announces that, effective Monday, 28 April 2025, the Company will transition its ne...

Cision • 25 Apr 08:00

Kallelse till årsstämma i Diagonal Bio AB

Aktieägarna i Diagonal Bio AB, org.nr 559248-8984, kallas härmed till årsstämma tisdagen den 20 maj 2025 kl.

Cision • 14 Apr 11:05

Diagonal Bio announces additional pilot tests of LAMPlify®

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") is pleased to announce that Diagonal Bio has signed an agreement to conduct pilot t...

Cision • 28 Mar 08:45

Diagonal Bio publishes Year-End Report for 2024

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") hereby publishes its year-end report for the financial year 2024.

Cision • 28 Mar 08:00

Diagonal Bio granted patent in Japan

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announces that the Japanese Patent Office has confirmed the grant of a patent (appl...

Cision • 21 Mar 14:00

Nomination Committee change in Diagonal Bio AB (publ.)

Diagonal Bio announces a change the Nomination Committee for the Annual General Meeting (AGM) on May 20, 2025.

Cision • 19 Mar 14:00

Trading in Diagonal Bio’s shares and warrants of series TO 2 on NGM Nordic SME begins today

Today, 19 March 2025, is the first day of trading in Diagonal Bio AB’s (publ) ("Diagonal Bio" or "the Company") securities on NGM Nordic SME...

Cision • 19 Mar 08:30

Stall Courant and Diagonal Bio agree to a pilot test of LAMPlify®

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") and Stall Courant, owned by Unibet founder Anders Ström and run by trotting trainer...

Cision • 13 Mar 09:45

Diagonal Bio has been approved for delisting from Nasdaq First North Growth Market

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") today announces that Nasdaq has approved Diagonal Bio's application for delisting f...

Cision • 04 Mar 16:44

Diagonal Bio has received conditional approval for listing on NGM Nordic SME

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") has received conditional approval for listing on NGM Nordic SME (“NGM”).

Cision • 04 Mar 15:42

Diagonal Bio applies for change of marketplace to NGM Nordic SME

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") today announces that the Company – in order to be able to reallocate costs – has de...

Cision • 03 Mar 09:54

Diagonal Bio AB’s announces last day of trading in BTU and first day of trading in warrants of series TO 2

Diagonal Bio AB's ("Diagonal Bio" or the "Company") rights issue of units, with a subscription period ending on 6 February 2025, has now bee...

Cision • 19 Feb 14:45

Diagonal Bio AB resolves on a directed issue of units to all external underwriters

The Board of Directors of Diagonal Bio AB ("Diagonal Bio" or the "Company") has today, based on the authorisation granted by the Extraordina...

Cision • 18 Feb 14:30

Diagonal Bio’s CEO Karin Wehlin increases ownership

Diagonal Bio AB’s (”Diagonal Bio” or the ”Company”) CEO, Karin Wehlin, has directly and through Wehlin’s fully owned company WW Advise AB pu...

Cision • 12 Feb 15:45

Diagonal Bio AB’s rights issue of units oversubscribed

The subscription period in Diagonal Bio AB’s ("Diagonal Bio" or the "Company") rights issue of units of initially approximately SEK 6.

Cision • 07 Feb 16:15

Stall Goop conducts pilot test of LAMPlify®

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") has signed an agreement with Stall Goop regarding a pilot test of LAMPlify®.

Cision • 05 Feb 19:45

TradeVenue intervjuar Diagonal Bios VD, Karin Wehlin

Cision • 03 Feb 13:00

Diagonal Bio announces positive pilot test results and secures order from StallZet

Diagonal Bio AB (publ) ("Diagonal Bio" or the "Company") announces an order valued at approximately SEK 150,000 from Daniel Redén, a renowne...

Cision • 29 Jan 09:40

The subscription period of Diagonal Bio AB’s rights issue of units commences today

Today, 23 January 2025, the subscription period in Diagonal Bio AB’s ("Diagonal Bio" or the "Company") rights issue of units of initially ap...

Cision • 23 Jan 08:30

Diagonal Bio AB publishes investment memorandum prior to upcoming rights issue of units

The subscription period of Diagonal Bio AB’s ("Diagonal Bio" or the "Company") rights issue of units, which was resolved on 23 December 2024...

Cision • 22 Jan 08:30

Nomination Committee change in Diagonal Bio (publ.)

Diagonal Bio announces a change the Nomination Committee for the Annual General Meeting (AGM) on May 20, 2025.

Cision • 17 Jan 15:30

Bulletin from the Extraordinary General Meeting of Diagonal Bio AB on 17 January 2025

Today, January 17, 2025, an Extraordinary General Meeting was held in Diagonal Bio AB.

Cision • 17 Jan 13:45

Diagonal Bio expands its testing panel for horses with EHV-5 detection

Diagonal Bio AB (publ) ("Diagonal Bio" or the "Company") announces the expansion of its equine diagnostic testing panel to include the detec...

Cision • 14 Jan 22:00

Kallelse till extra bolagsstämma i Diagonal Bio AB

Aktieägarna i Diagonal Bio AB, org.nr 559248-8984, kallas härmed till extra bolagsstämma fredagen den 17 januari 2025 kl.

Cision • 23 Dec 2024 23:02

The Board of Directors of Diagonal Bio AB resolves on a directed issue of units and a rights issue of units to focus on validation of LAMPlify®’s commercial interest

Board of Directors of Diagonal Bio AB (”Diagonal Bio” or the ”Company”) has today resolved on a directed issue of units consisting of shares...

Cision • 23 Dec 2024 22:54

Diagonal Bio enters into a strategic partnership with Daniel Redén at StallZet to enhance commercialisation plans

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announces that Daniel Redén, a renowned horse trainer at StallZet, has entered into...

Cision • 23 Dec 2024 21:46

Renowned horse race jockey and trainer conducts pilot test of LAMPlify®

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announces that one of Sweden’s most accomplished horse race trainers, Madeleine Smi...

Cision • 22 Nov 2024 12:30

Valberedning utsedd i Diagonal Bio AB (publ) inför årsstämman 2025

I enlighet med de principer för inrättande av valberedning som tidigare beslutats på årsstämman 2024, har följande valberedning utsetts för ...

Cision • 18 Nov 2024 16:00

Nomination Committee appointed for Diagonal Bio

Diagonal Bio today announces that the Nomination Committee has been appointed in preparation for the Annual General Meeting (AGM) on May 20,...

Cision • 18 Nov 2024 16:00

Diagonal Bio announces pilot test with LAMPlify® at Kolgjini Stables

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announces a partnership with Kolgjini Stables (Stall Kolgjini), founded by renowned...

Cision • 13 Nov 2024 15:00

Diagonal Bio announces that it is exploring financing options

Diagonal Bio AB ("Diagonal Bio" or "the Company") today announces that the Board of Directors of the Company has engaged financial and legal...

Cision • 11 Nov 2024 08:00

Diagonal announces first pilot test at a stud with LAMPlify®

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announces a partnership with Gocksta Stud (Gocksta Stuteri), led by Anne-Sophie Thi...

Cision • 31 Oct 2024 15:00

Diagonal Bio AB Third Quarter Report (Q3 2024)

“One of the most exciting developments is our effort into a new application of our technology LAMPlify®—this time in the domain of swine dis...

Cision • 31 Oct 2024 08:00

Diagonal Bio announces pilot test of LAMPlify® at Norwegian University of Life Sciences

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announces the commencement of a six-month pilot test of its point-of-care diagnosti...

Cision • 25 Oct 2024 14:15

Diagonal Bio will present LAMPlify® at a partnered event for trainers at Jägersro

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") will be participating in a partnered event with Svensk Galopp, at Jägersro on Novem...

Cision • 22 Oct 2024 14:31

Diagonal Bio announces successful external validation of LAMPlify® for viruses in pigs

Diagonal Bio AB (publ) (“Diagonal” or “the Company”) announces successful results of a recent pilot study conducted by the Centre for Diagno...

Cision • 11 Oct 2024 14:30

Hunneberga Horse Stable to conduct pilot test of LAMPlify®

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announces that Hunneberga Horse Stable (Hunneberga Hästgård) and Tomas Hammar, show...

Cision • 08 Oct 2024 19:00

Horse trainer Daniel Redén at StallZet will conduct a pilot with LAMPlify®

Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) has partnered with StallZet and Daniel Redén, one of Sweden's leading horse trottin...

Cision • 03 Oct 2024 12:15

Diagonal Bio AB’s warrant exercise registered at the Swedish Companies Registration Office

Diagonal Bio AB ("Diagonal" or the "Company") today announces that the new shares from the exercise of warrants of series TO 1 have been reg...

Cision • 02 Oct 2024 17:34

Diagonal Bio AB announces the outcome of the exercise of warrants of series TO 1

On September 26, 2024, the exercise period for Diagonal Bio AB's ("Diagonal" or the "Company") warrants of series TO 1 ("TO 1") ended.

Cision • 27 Sep 2024 12:38

The last day of trading in warrants of series TO 1 is on the 24th of September 2024

The 24th of September 2024 is the last day of trading in warrants of series TO 1, which were issued in connection with Diagonal Bio AB's ("D...

Cision • 19 Sep 2024 08:30

The exercise period for warrants of series TO 1 commences today

Today is the first day for the exercise of Diagonal Bio AB's ("Diagonal Bio" or "the Company") warrants of series TO 1 ("TO 1") which were i...

Cision • 12 Sep 2024 08:30

The exercise price for warrants of series TO 1 has been set to SEK 0,05 per new share

Diagonal Bio AB ("Diagonal Bio" or "the Company") hereby announces that the exercise price for the warrants of series TO 1 (”TO 1”), which w...

Cision • 11 Sep 2024 09:00

Diagonal Bio announces successful external validation of LAMPlify® for respiratory viruses in horses

Diagonal Bio AB (publ) (“Diagonal Bio” and “the Company”) announces that its diagnostic tool, LAMPlify® has undergone a successful external ...

Cision • 06 Sep 2024 11:30

Diagonal Bio AB Second Quarter Report (Q2 2024)

“In the second quarter of 2024, we have made advancements, particularly within the equine healthcare sector (horse veterinary clinics) where...

Cision • 22 Aug 2024 08:00

Diagonal Bio receives order from the Technical University of Denmark

Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) has secured an order from the Technical University of Denmark (“DTU”) valued at jus...

Cision • 21 Aug 2024 15:10

Kommuniké från årsstämma den 11 juni 2024 i Diagonal Bio AB

Idag, den 11 juni 2024, hölls årsstämma i Diagonal Bio AB.

Cision • 11 Jun 2024 15:00

Bulletin from the Annual General Meeting on 11 June 2024 in Diagonal Bio AB

Today, on 11 June 2024, the Annual General Meeting of Diagonal Bio AB was held.

Cision • 11 Jun 2024 15:00

Diagonal Bio AB first quarter (Q1 2024)

“The end of last year was marked by our focus on creating the business platform to generate the company's initial revenue in 2024.

Cision • 31 May 2024 08:00

Diagonal Bio appoints new CFO

Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) has appointed Fata Mrsic as the new Chief Financial Officer (CFO).

Cision • 23 May 2024 14:47

Diagonal Bio announces strategic pilot study with Löberöds Hästklinik

Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) is pleased to announce a significant new collaboration with Löberöds Hästklinik, le...

Cision • 15 May 2024 12:30

Diagonal Bio AB Annual Report 2023

The Board of Directors and CEO of Diagonal Bio AB hereby publish the Annual Report for the fiscal year 2023.

Cision • 15 May 2024 10:42

Kallelse till årsstämma i Diagonal Bio AB

Aktieägarna i Diagonal Bio AB (publ), org.nr 559248-8984, (”Bolaget”) kallas härmed till årsstämma tisdagen den 11 juni 2024 kl.

Cision • 14 May 2024 08:00

Diagonal Bio AB announces last day of trading in BTU and first day of trading in TO 1

Diagonal Bio AB's ("Diagonal Bio" or the "Company") rights issue of units, with a subscription period ending on April 22, 2024, has now been...

Cision • 07 May 2024 16:00

Diagonal Bio AB announces outcome of rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW Z...

Cision • 24 Apr 2024 09:30

BioStock: Emission ska möjliggöra Diagonal Bios kommersialisering

Lundabolaget Diagonal Bio har kommit långt på mycket kort tid.

Cision • 17 Apr 2024 08:15

Diagonal Bio AB publish – White paper

Diagonal Bio’s platforms using an 8-parallel test format, show overall Accuracy of 99.

Cision • 16 Apr 2024 14:31

BioStock Investor Pitch: Diagonal Bio

Hur kan bolagets utveckling ha gått så snabbt? Diagonal Bio vill hindra spridning av infektioner genom att utveckla snabba och säkra tester ...

Cision • 15 Apr 2024 08:45

BioStock: Diagonal Bio demonstrerar snabb och säker diagnostik

Diagonal Bio siktar på att ge säkra diagnostiska svar på tio minuter.

Cision • 10 Apr 2024 08:15

Diagonal Bio AB strengthens its go-to-market strategy through an agreement with founding partner Johan Källstrand

Diagonal Bio AB (publ) ("Diagonal Bio" or the "Company") today announces a strategic step to strengthen its sales and marketing efforts.

Cision • 10 Apr 2024 08:00

Diagonal Bios vd: ”Produkt på väg till marknad men vi värderas som nystartat bolag”

På bara tre år har Diagonal Bio gått från nystartat utvecklingsbolag till att glänta på dörren till marknaden med sin första diagnostiska pr...

Cision • 08 Apr 2024 08:15

The subscription period in Diagonal Bio AB rights issue commences today

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW Z...

Cision • 08 Apr 2024 08:00

Diagonal Bio announces successful pilot study results and extended partnership with Hørsholm Veterinary Clinic

Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) announces the extension of its partnership with Hørsholm Veterinary Clinic followin...

Cision • 05 Apr 2024 15:00

Diagonal Bio AB publishes a prospectus because of upcoming rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW Z...

Cision • 03 Apr 2024 18:00

Bulletin from the Extraordinary General Meeting on Tuesday 2[nd] of April in Diagonal Bio AB

Today, 2[nd] April 2024, an Extraordinary General Meeting was held in Diagonal Bio AB, reg.

Cision • 02 Apr 2024 14:00

Diagonal Bio appoints Karin Wehlin as new CEO

Diagonal Bio AB (publ.) (“Diagonal Bio” or “the Company”) is pleased to announce that the Board of Directors has appointed Karin Wehlin as C...

Cision • 28 Feb 2024 17:50

Notice to attend the extraordinary general meeting of Diagonal Bio AB

Shareholders in Diagonal Bio AB, 559248-8984, are hereby invited to attend an extraordinary general meeting on Tuesday, 2nd of April, 2024, ...

Cision • 28 Feb 2024 17:45

The Board of Directors decides on a preferential rights issue of units in order to finance future development

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW Z...

Cision • 28 Feb 2024 17:40

Diagonal Bio AB Year-end Report 2023

“Looking back at 2023, I am proud to point out the significant steps we have made in our development, including the key achievements such as...

Cision • 28 Feb 2024 17:31

Diagonal Bio AB has signed a distribution agreement with Techtum Lab AB

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") has signed a distribution agreement with Techtum Lab AB ("Techtum Lab").

Cision • 16 Feb 2024 14:39

Diagonal Bio AB (publ) genomför en effektivisering av marknadskommunikation och ändrar från svenska till engelska för pressreleaser och delårsrapporter.

Diagonal Bio (“Bolaget”) meddelar att Bolaget valt att effektivisera sin marknadskommunikation och framöver endast kommer att tillhandahålla...

Cision • 14 Feb 2024 08:00

Diagonal Bio AB (publ) lämnar uppdatering kring den finansiella situationen

I augusti 2023 kommunicerades att Diagonal Bio erhöll en finansiering där lån och nytt ägarkapital skulle ta bolaget till Q1 2024.

Cision • 02 Feb 2024 08:00

Kvalificerade personaloptioner och teckningsoptioner i Diagonal Bio AB (publ.) avslutas

I enlighet med den överenskommelse som gjordes i samband med Jack Egelund Madsens avgång som VD den 23 november 2023, har styrelsen idag på ...

Cision • 20 Dec 2023 17:30

Valberedning utsedd i Diagonal Bio AB (publ.) inför årsstämman 2024

I enlighet med de principer för inrättande av valberedning som tidigare beslutats på årsstämman 2023, har följande valberedning utsetts för ...

Cision • 04 Dec 2023 15:00

Rättelse avseende felaktigt utskick av pressmeddelande

Rättelse: 2023-11-27 kl 10:11:38 skickade Bolaget felaktigt ut ett tidigare publicerat press meddelande från 2023-03-06.

Cision • 27 Nov 2023 11:22

Diagonal Bio ingår avtal med veterinärklinik

Diagonal Bio AB (publ) ("Diagonal Bio" eller "Företaget") meddelar att företaget har ingått ett avtal med en Hörsholms Hästepraksis rörande ...

Cision • 27 Nov 2023 10:48

Diagonal Bio AB publicerar en strategiuppdatering med uppsatta milstolpar samt marknads- och försäljningsstrategi för 2023

Diagonal Bio AB (publ) (”Diagonal” eller ”Bolaget”) har satt upp fokusområden för sina teknologier LAMPlify™ (testsystemet på mindre reglera...

Cision • 27 Nov 2023 10:11

Karin Wehlin utsedd till tillförordnad VD för Diagonal Bio

Styrelsen i Diagonal Bio AB (publ.) (”Diagonal” eller ”Bolaget”) har utsett styrelseledamot Karin Wehlin som tillförordnad VD.

Cision • 23 Nov 2023 17:37

Diagonal Bio AB initierar pilotstudie med Techtum Lab

Diagonal Bio AB (publ) (“Diagonal Bio” eller “Bolaget”) meddelar att bolaget initierar en pilotstudie med Techtum Lab AB.

Cision • 14 Nov 2023 12:41

Diagonal Bio AB offentliggör delårsrapport 1 januari – 30 september 2023

Diagonal Bio AB (publ) ("Diagonal" eller "Bolaget") offentliggör härmed delårsrapport för perioden 1 januari - 30 september 2023.

Cision • 31 Oct 2023 07:30

Diagonal Bio ger uppdatering om IP-status för kärnteknologin

Diagonal Bio AB (publ) (“Diagonal Bio” eller “Bolaget”) presenterar idag en uppdatering om Bolagets arbete för att säkra IP-skydd för kärnte...

Cision • 27 Oct 2023 16:24

Diagonal Bio AB meddelar registrering av riktad nyemission i enlighet med beslut på extra bolagsstämma den 22 september 2023.

Idag, den 3 oktober 2023, meddelar Diagonal Bio AB (publ) (”Diagonal Bio” eller ”Bolaget”) registreringen av den riktade nyemissionen i enli...

Cision • 03 Oct 2023 15:41

Diagonal Bio etablerar ett Advisory Board med rådgivare inom kommersialisering

Diagonal Bio AB ("Diagonal Bio" eller "Bolaget") etablerar en Advisory Board med rådgivare som har kompetens och erfarenhet från kommersiali...

Cision • 26 Sep 2023 11:39

Kommuniké från extra bolagsstämma fredagen den 22 september i Diagonal Bio AB

Idag, den 22 september 2023, hölls extra bolagsstämma i Diagonal Bio AB, org.

Cision • 22 Sep 2023 13:18

Diagonal Bio AB i en VD-intervju

Jack Egelund Madsen, VD för Diagonal Bio AB (publ) (”Diagonal” eller ”Bolaget”) intervjuas av Impala Nordic som uppföljning av Bolagets Q2-r...

Cision • 15 Sep 2023 16:08